STING1 and cancer: Combinatorial use of STING and anti PD-1/PD-L1 is an attractive therapeutic strategy since STING agonists increase T cell infiltration and PD-L1 expression within the TME.63,102,113,114 Additional potential synergistic effects include promoting M2 repolarization to the M1 phenotype and increasing NK cell infiltration.37,44,115 This treatment approach has been evaluated in multiple preclinical studies with varying degrees of success in non-GBM cancer models.35,81,102,113,114,116,117